Table 2.

Odds ratio estimates (confidence interval or credible interval) for CRC corresponding to statin users vs non-users across genotype sub-groups. Under all five methods, a model with main effect of G₁, G₂, E controlling for S was fit as in Table 1. Common allele in G₁ (RS1800775 on CETP) and G₂ (RS1056836 on CYP1B1) are A and C respectively and minor allele in G₁ and G₂ are C and G respectively.

	Statins	Statins	Statins	Statins	Statins
G1	A/A	A/C	C/C	A/A	A/A
G2	C/C	C/C	C/C	G/C	G/G
TPFB	0.27 (0.15, 0.39)	0.35 (0.22, 0.44)	0.48 (0.26, 0.65)	0.38 (0.24, 0.51)	0.48 (0.30, 0.77)
TPFBemp	0.26 (0.15, 0.42)	0.36 (0.23, 0.45)	0.49 (0.31, 0.69)	0.37 (0.23, 0.50)	0.50 (0.31, 0.79)
WL	0.27 (0.15, 0.49)	0.35 (0.22, 0.55)	0.45 (0.26, 0.77)	0.40 (0.26, 0.62)	0.59 (0.34, 1.02)
PL	0.27 (0.15, 0.49)	0.35 (0.22, 0.55)	0.45 (0.26, 0.79)	0.40 (0.25, 0.63)	0.59 (0.33, 1.05)
UML	0.25 (0.14, 0.44)	0.32 (0.20, 0.50)	0.41 (0.23, 0.72)	0.36 (0.23, 0.57)	0.53 (0.29, 0.95)
CML	0.22 (0.12, 0.37)	0.33 (0.21, 0.51)	0.49 (0.29, 0.83)	0.34 (0.20, 0.48)	0.46 (0.26, 0.80)
EB	0.22 (0.13, 0.39)	0.31 (0.20, 0.49)	0.43 (0.24, 0.79)	0.32 (0.21, 0.49)	0.47 (0.27, 0.82)

^†TPFB, TPFB_emp: Two-phase full Bayes (with empirical estimates for prior variances), UML: Unconstrained maximum likelihood, CML: Constrained maximum likelihood, EB: Empirical-Bayes, WL: weighted likelihood, and PL: pseudo-likelihood